Completed PHASE2 INTERVENTIONAL 1-arm NCT04005170

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

A Phase II Trial of Combination of Toripalimab and Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Sponsor: Mian XI

Conditions Unresectable Esophageal Cancer

Interventions Intensity-modulated radiotherapy Paclitaxel/Cisplatin Toripalimab

Updated 6 times since 2019 Last updated: Aug 21, 2022 Started: Jun 25, 2019 Primary completion: Dec 31, 2020 Completion: Jul 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04005170, this PHASE2 trial focuses on Unresectable Esophageal Cancer and remains completed. Sponsored by Mian XI, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Apr 2021 — Sep 2022 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Aug 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mian XI

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guanzhou, China